The World Health Organization (WHO) classification of the myeloid neoplasms.

By J. Vardiman, N. Harris, R. Brunning. Blood, 2002

2,304 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/4a388b3847ca106c5d2b64c850c588dbea92378e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Andreas Hochhaus
2. H. Kantarjian

In Hematology

1. Andreas Hochhaus
2. H. Kantarjian
3. Brian J. Druker

Citations in the corpus

• Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. (2007, methodology): “As compared with the four groups defined by the IPSS, WPSS was able to identify five risk groups of MDS patients with different survival and risk of AML.”
• Report of an international working group to standardize response criteria for myelodysplastic syndromes. (2000, background): “The specific cytogenetic abnormalities common to MDS, alkylating-agent–related AML, and poor-prognosis AML (3q2, 25, 5q2, 27, 7q2, 18, 19, 11q2, 12p2, 218, 219, 20q2, 121, t(1;7), t(2;11), complex karyotypes) likely reflect a common pathogenesis of these lesions, distinct from that of other de novo ”
• Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia (2009, methodology): “According to the FAB (Bennett et al, 1982, 1994) and WHO (Vardiman et al, 2002) criteria, the series of CMML comprised 21 myeloproliferative (MP-CMML), 18 myelodysplastic (MD-CMML) forms and seven acutelytransformed CMMLs (AT-CMML).”
• Chronic Myeloid Leukemia (2007, neutral): “The Philadelphia chromosome is a reciprocal translocation between the long arms of chromosomes 9 and 22: t(9,22)(q34;q11).”
• Acute Myeloid Leukaemia: New Targets and Therapies (2017, background): “A new World Health Organization (WHO) classification introduced four main AML groups, based on cytogenetic abnormalities, and is important to the approach used to treat this disease [5].”
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, background): “Although a clear cutoff of bone marrow blasts to discriminate between MDS and AML cannot be easily defined, several studies suggest that patients with 20% to 29% blasts often have clinical features, including response to therapy and survival times, similar to patients with 30% or more blasts.(86) Ac”
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms (2008, background): “Over the years, erythroleukemia has been re-defined as acute erythroid leukemia or its variants”
• Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. (2008, neutral): “70 to 79 y 1909 43 (40-46) 1007 73 (69-77) 212 22 (15-30) 80 y and older 1924 37 (34-41) 738 66 (63-70) 202 12 (5-20) Race White 4740 44 (42-46) 3216 80 (78-82) 510 21 (16-26) Black 422 49 (42-56) 344 72 (65-78) 33 15 (0-32)”
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “Median d from diagnosis to trial entry (range) 21 (6-166)”
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005, background): “The fact that (1) the mutation was present at a level substantially less than the wild-type allele in many heterozygous cases, (2) the wild-type allele was detectable in the great majority of homozygous patients, and (3) the age of homozygous cases (median, 63 years; range, 17-69 years) was not sign”